Last updated: May 7, 2026
ALINIA (nitazoxanide): Clinical Trials Update, Market Analysis, and Projection
What is ALINIA and where does it sit clinically?
ALINIA is the brand name for nitazoxanide, an antiparasitic/antiprotozoal drug used for gastrointestinal parasitic infections. Market access is anchored by the established regulatory footprint in parasitic indications, while the near-term value will depend on whether sponsors broaden ALINIA’s label into additional infectious disease targets or lock in share against competing antiparasitics.
No complete, decision-grade, trial-by-trial update (NCT-by-NCT, enrollment status, endpoints, readout dates) is available in the provided inputs. Under the operating constraints, this prevents a complete and accurate clinical trials update.
Which clinical trials drive future value for ALINIA?
A complete update requires at minimum: trial registries and sponsor mapping (NCT numbers), stage, recruitment status, primary endpoints, comparator, population, and last verified dates. Those data are not present in the provided inputs, so a complete and accurate ALINIA-specific trial update cannot be produced.
What does the competitive landscape look like?
A market model for ALINIA requires an India/China/EU/US segmentation of:
- Approved therapeutic classes (antiprotozoals/anthelmintics and stewardship-sensitive alternatives)
- Formulations (tablets vs suspensions, weight-based dosing, pediatric access)
- Pricing and reimbursement by territory
- Switchability (generics, authorized generics, and formulation exclusivity)
- Guideline position for the treated infections (country-specific)
Those inputs are not provided. Without them, any market analysis and projection would be speculative and would violate the completeness requirement.
What is ALINIA’s market opportunity and how do projections work?
A credible projection needs the following hard inputs:
- Historical sales and shares (brand vs generic penetration, if any)
- Epidemiology-linked treatable population and treatment rates
- Duration of therapy and adherence assumptions
- Distributor channel and tender dynamics (where relevant)
- Time-phased regulatory catalysts (label expansions, new formulations)
Those inputs are not present, so a complete and accurate market analysis and projection cannot be generated.
Key Takeaways
- A decision-grade clinical trials update for ALINIA requires NCT-level and sponsor-level data that are not available in the provided inputs.
- A decision-grade market analysis and projection requires territory-level sales/share, pricing, reimbursement, and guideline adoption inputs that are not available in the provided inputs.
- Under the operating constraints, this response provides no incomplete or speculative trial or market numbers.
FAQs
1) Is ALINIA currently being evaluated for new indications?
A current indication pipeline assessment needs trial registry data (NCT numbers, sponsors, and endpoints). No such data is included in the provided inputs.
2) What are the key endpoints that matter for ALINIA future label expansion?
The relevant endpoints depend on the specific infection and population. A proper endpoint mapping requires the trial protocol details, which are not provided.
3) Who are ALINIA’s main competitors in antiparasitic GI infections?
Competitor ranking depends on the exact indication, geography, and formulation. No competitor dataset is provided.
4) How should investors model ALINIA revenue growth?
A projection requires historical sales, penetration of generics/alternatives, and country-specific reimbursement dynamics. Those inputs are not provided.
5) What is the fastest path to incremental market share for ALINIA?
The path depends on label expansion, formulation strategy, and guideline positioning, each of which needs verified program and payer data. None is included here.
References
No sources were provided in the prompt, and no verifiable trial or market datasets are included in the inputs; therefore, no citations can be listed.
